The Central European Biotech Incubator and Accelerator (CEBINA) has announced a partnership with Ursapharm Arzneimittel to repurpose Ursapharm’s Pollival azelastine nasal spray for the treatment of COVID-19. In July 2020, CEBINA announced that it had filed a patent application for the use of azelastine to treat COVID-19 and that it was looking for partners to develop a nasal spray for that indication.
According to the announcement, the company has already initiated a clinical trial to evaluate the ability of Pollival to reduce viral load in the nasal cavity. CEBINA announced last fall that azelastine nasal spray demonstrated “potent efficacy against SARS-CoV-2” in a human nasal tissue model.
Read the CEBINA press release.
